ACCD241220C2500
- 0.95
- +0.05+5.56%
Accolade Newsroom
Breaking Down Accolade: 8 Analysts Share Their Views
Accolade Is Maintained at Equal-Weight by Morgan Stanley
Morgan Stanley Maintains Accolade(ACCD.US) With Hold Rating, Cuts Target Price to $5
FDA Roundup: December 17, 2024
Accolade to Announce Fiscal Third Quarter 2025 Financial Results
Insider Sale: President of $ACCD (ACCD) Sells 5,582 Shares
Stocks With Improving and Deteriorating 'TechniGrade' by Piper Sandler
Accolade (ACCD) Upgraded to Buy: Here's Why
Accolade To Present at Upcoming Investor Conferences
Accolade Welcomes Renalogic to Trusted Partner Ecosystem
Wells Fargo Maintains Accolade(ACCD.US) With Hold Rating, Maintains Target Price $6
Wells Fargo Maintains Accolade(ACCD.US) With Hold Rating, Cuts Target Price to $6
A Quick Look at Today's Ratings for Accolade(ACCD.US), With a Forecast Between $5 to $8
Forecasting The Future: 6 Analyst Projections For Accolade
Accolade Price Target Cut to $5.00/Share From $5.50 by Barclays
Accolade Is Maintained at Equal-Weight by Barclays
Express News | Stephens & Co. Maintains Overweight on Accolade, Lowers Price Target to $8
A Quick Look at Today's Ratings for Accolade(ACCD.US), With a Forecast Between $5 to $9
Express News | Accolade Inc : Canaccord Genuity Cuts Target Price to $7 From $13
Accolade Inc (ACCD) Q2 2025 Earnings Call Transcript Highlights: Strong Revenue and Cash Flow ...